{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:38:57Z","timestamp":1793597937271,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Diabetes Therapies Evaluation Network Limited","award":["CREDENCE\/2021\/01"],"award-info":[{"award-number":["CREDENCE\/2021\/01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,20]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Observational studies suggest sodium-glucose co-transporter 2 (SGLT2) inhibitor kidney outcome trials are not representative of the broader population of people with chronic kidney disease (CKD). However, there are limited data on the generalizability to those without co-existing type 2 diabetes (T2D), and the representativeness of the Study of Heart and Kidney Protection with Empagliflozin (EMPA-KIDNEY) trial has not been adequately explored. We hypothesized that SGLT2 inhibitor kidney outcome trials are more representative of people with co-existing T2D than those without, and that EMPA-KIDNEY is more representative than previous trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A cross-sectional analysis of adults with CKD in English primary care was conducted using the Oxford-Royal College of General Practitioners Clinical Informatics Digital Hub. The proportions that met the eligibility criteria of SGLT2 inhibitor kidney outcome trials were determined, and their characteristics described. Logistic regression analyses were performed to identify factors associated with trial eligibility.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 6\u2003670\u2003829 adults, 516\u2003491 (7.7%) with CKD were identified. In the real-world CKD population, 0.9%, 2.2% and 8.0% met the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), Dapagliflozin and Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD) and EMPA-KIDNEY eligibility criteria, respectively. All trials were more representative of people with co-existing T2D than those without T2D. Trial participants were 9\u201314 years younger than the real-world CKD population, and had more advanced CKD, including higher levels of albuminuria. A higher proportion of the CREDENCE (100%), DAPA-CKD (67.6%) and EMPA-KIDNEY (44.5%) trial participants had T2D compared with the real-world CKD population (32.8%). Renin\u2013angiotensin system inhibitors were prescribed in almost all trial participants, compared with less than half of the real-world CKD population. Females were under-represented and less likely to be eligible for the trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>SGLT2 inhibitor kidney outcome trials represent a subgroup of people with CKD at high risk of adverse kidney events. Our study highlights the importance of complementing trials with real-world studies, exploring the effectiveness of SGLT2 inhibitors in the broader population of people with CKD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfae071","type":"journal-article","created":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T07:58:13Z","timestamp":1711180693000},"page":"71-82","source":"Crossref","is-referenced-by-count":14,"title":["A comparison of sodium-glucose co-transporter 2 inhibitor kidney outcome trial participants with a real-world chronic kidney disease primary care population"],"prefix":"10.1093","volume":"40","author":[{"given":"Anna K","family":"Forbes","sequence":"first","affiliation":[{"name":"Renal Services, Epsom & St Helier University Hospitals NHS Trust , London ,","place":["UK"]},{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford , Oxford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hinton","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford , Oxford ,","place":["UK"]},{"name":"Department of Clinical and Experimental Medicine, University of Surrey , Guildford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Feher","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford , Oxford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Elson","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford , Oxford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M","family":"Ord\u00f3\u00f1ez-Mena","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford , Oxford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Joy","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford , Oxford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejuan","family":"Fan","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford , Oxford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6863-2325","authenticated-orcid":false,"given":"Debasish","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Renal & Transplantation Unit, St George's University Hospitals NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas I","family":"Cole","sequence":"additional","affiliation":[{"name":"Renal Services, Epsom & St Helier University Hospitals NHS Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Munro","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Surrey , Guildford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Whyte","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Surrey , Guildford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J","family":"Suckling","sequence":"additional","affiliation":[{"name":"Renal Services, Epsom & St Helier University Hospitals NHS Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2568-9871","authenticated-orcid":false,"given":"Pauline A","family":"Swift","sequence":"additional","affiliation":[{"name":"Renal Services, Epsom & St Helier University Hospitals NHS Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-2641","authenticated-orcid":false,"given":"Simon","family":"de Lusignan","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford , Oxford ,","place":["UK"]},{"name":"Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC), Royal College of General Practitioners , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"key":"2025010614201559500_bib1","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 Diabetes, 2022. A consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"2025010614201559500_bib2","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2025010614201559500_bib3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2025010614201559500_bib4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2025010614201559500_bib5","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1016\/j.jacc.2020.09.616","article-title":"U.S. Prevalence of individuals with diabetes and chronic kidney disease indicated for SGLT-2 inhibitor therapy","volume":"76","author":"Aggarwal","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025010614201559500_bib6","first-page":"3","article-title":"Applicability of renal outcome trials of canagliflozin to the real world: implications from comparisons of characteristics between trial patients and real-life patients","volume":"29","author":"Ling-Chen","year":"2020","journal-title":"Pharmacoepidemiol Drug Safety"},{"key":"2025010614201559500_bib7","doi-asserted-by":"publisher","first-page":"e007875","DOI":"10.1161\/CIRCOUTCOMES.121.007875","article-title":"Generalizability of DAPA-CKD to the United States","volume-title":"Circ Cardiovasc Qual Outcomes","author":"Aggarwal","year":"2021"},{"key":"2025010614201559500_bib8","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1093\/ndt\/gfac276","article-title":"Generalizability of DAPA-CKD trial to the real-world setting of outpatient CKD clinics in Italy","volume":"37","author":"Minutolo","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2025010614201559500_bib9","doi-asserted-by":"publisher","first-page":"100349","DOI":"10.1016\/j.jacadv.2023.100349","article-title":"Individuals with chronic kidney disease qualifying for SGLT-2 inhibitors in the United States and EMPA-KIDNEY generalizability","volume":"2","author":"Chiu","year":"2023","journal-title":"JACC Adv"},{"key":"2025010614201559500_bib10","doi-asserted-by":"publisher","first-page":"105530","DOI":"10.1016\/j.phrs.2021.105530","article-title":"Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: impact of the 2020 KDIGO clinical practice guidelines","volume":"166","author":"Ciardullo","year":"2021","journal-title":"Pharmacol Res"},{"key":"2025010614201559500_bib11","doi-asserted-by":"publisher","first-page":"e39141","DOI":"10.2196\/39141","article-title":"Representativeness, vaccination uptake, and COVID-19 clinical outcomes 2020-2021 in the UK Oxford-Royal College of General Practitioners Research and Surveillance Network: cohort profile summary","volume":"8","author":"Leston","year":"2022","journal-title":"JMIR Public Health Surveill"},{"key":"2025010614201559500_bib12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12882-018-0882-9","article-title":"An ontological approach to identifying cases of chronic kidney disease from routine primary care data: a cross-sectional study","volume-title":"BMC Nephrol","author":"Cole","year":"2018"},{"key":"2025010614201559500_bib13","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2025010614201559500_bib14","author":"Office for National Statistics"},{"key":"2025010614201559500_bib15","article-title":"English indices of deprivation 2019: research report","author":"Ministry of Housing Communities & Local Government"},{"key":"2025010614201559500_bib16","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1111\/jgs.16749","article-title":"Generalizability of blood pressure lowering trials to older patients: cross-sectional analysis","volume":"68","author":"Sheppard","year":"2020","journal-title":"J Am Geriatr Soc"},{"key":"2025010614201559500_bib17","doi-asserted-by":"publisher","first-page":"b2393","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls","volume":"338","author":"Sterne","year":"2009","journal-title":"BMJ"},{"key":"2025010614201559500_bib18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"2025010614201559500_bib19","article-title":"stddiff: calculate the standardized difference for numeric, binary and category variables","author":"Du","year":"2022"},{"key":"2025010614201559500_bib20","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.3399\/BJGP.2022.0235","article-title":"Development of a modified Cambridge Multimorbidity Score for use with SNOMED CT: an observational English primary care sentinel network study","volume":"73","author":"Tsang","year":"2023","journal-title":"Br J Gen Pract"},{"key":"2025010614201559500_bib21","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1016\/j.mayocp.2020.12.038","article-title":"Barriers to ACEI\/ARB use in proteinuric chronic kidney disease: an observational study","volume-title":"Mayo Clin Proc","author":"McCoy","year":"2021"},{"key":"2025010614201559500_bib22","doi-asserted-by":"publisher","first-page":"e1918169","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry","volume":"2","author":"Tuttle","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2025010614201559500_bib23","doi-asserted-by":"publisher","first-page":"e2113749","DOI":"10.1001\/jamanetworkopen.2021.13749","article-title":"Analysis of female enrollment and participant sex by burden of disease in US clinical trials between 2000 and 2020","volume":"4","author":"Steinberg","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025010614201559500_bib24","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S2213-2600(22)00003-0","article-title":"It is time to include real-world effectiveness data on medicinal product labels","volume":"10","author":"Dal-Re","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2025010614201559500_bib25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/picr.picr_62_21","article-title":"Introduction to real-world evidence studies","volume":"12","author":"Chodankar","year":"2021","journal-title":"Perspect Clin Res"},{"key":"2025010614201559500_bib26","doi-asserted-by":"publisher","first-page":"368","DOI":"10.14236\/jhi.v22i3.177","article-title":"Creating and using real-world evidence to answer questions about clinical effectiveness","volume":"22","author":"de Lusignan","year":"2015","journal-title":"J Innov Health Inform"},{"key":"2025010614201559500_bib27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial","volume":"12","author":"EMPA-KIDNEY Collaborative Group","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025010614201559500_bib28","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group SGLT Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet"},{"key":"2025010614201559500_bib29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/amiajnl-2011-000681","article-title":"Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research","volume":"20","author":"Weiskopf","year":"2013","journal-title":"J Am Med Inform Assoc"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfae071\/58780578\/gfae071.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/1\/71\/58780578\/gfae071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/1\/71\/58780578\/gfae071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T14:20:28Z","timestamp":1736173228000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/1\/71\/7633975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3,22]]},"published-print":{"date-parts":[[2024,12,20]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae071","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,3,22]]}}}